Botulinum toxin therapy for neuropsychiatric disorders

Details Botulinum toxin therapy for neuropsychiatric disorders Botulinum toxin therapy for neuropsychiatric disorders

2007-05-16

2010-10-12

Mondesi, Robert B (Department: 1645)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Bacterium or component thereof or substance produced by said...

C424S184100

Reexamination Certificate

active

07811587

ABSTRACT:
Methods for treating psychiatric disorders include intracranial administration of a therapeutically effective amount of a neurotoxin, such as a botulinum toxin type A, to a human patient.

REFERENCES:
patent: 4741902 (1988-05-01), Haast
patent: 5352447 (1994-10-01), Johnson
patent: 5545617 (1996-08-01), Dartt et al.
patent: 5549884 (1996-08-01), Weinberger et al.
patent: 5562907 (1996-10-01), Arnon
patent: 5714468 (1998-02-01), Binder
patent: 5766605 (1998-06-01), Sanders et al.
patent: 5843971 (1998-12-01), Boer et al.
patent: 5989545 (1999-11-01), Foster et al.
patent: 6113915 (2000-09-01), Aoki et al.
patent: 6203794 (2001-03-01), Dolly et al.
patent: 6235289 (2001-05-01), Aoki
patent: 6272370 (2001-08-01), Gilles et al.
patent: 6290961 (2001-09-01), Aoki
patent: 6306403 (2001-10-01), Donovan
patent: 6306423 (2001-10-01), Donovan et al.
patent: 6312708 (2001-11-01), Donovan
patent: 6319505 (2001-11-01), Aoki
patent: 6333037 (2001-12-01), Aoki
patent: 6372226 (2002-04-01), Aoki
patent: 6383509 (2002-05-01), Donovan et al.
patent: 6429189 (2002-08-01), Borodic
patent: 6447787 (2002-09-01), Gassner et al.
patent: 6451544 (2002-09-01), Giulian
patent: 6458365 (2002-10-01), Aoki
patent: 6464986 (2002-10-01), Aoki
patent: 6475745 (2002-11-01), Giulian
patent: 6506399 (2003-01-01), Donovan
patent: 6524580 (2003-02-01), Donovan
patent: 6545126 (2003-04-01), Johnson et al.
patent: 6585970 (2003-07-01), Donovan
patent: 6585993 (2003-07-01), Donovan et al.
patent: 6620415 (2003-09-01), Donovan
patent: 6623742 (2003-09-01), Voet
patent: 6645496 (2003-11-01), Aoki
patent: 6645500 (2003-11-01), Halkier et al.
patent: 6716427 (2004-04-01), Donovan
patent: 6743424 (2004-06-01), Donovan
patent: 6827931 (2004-12-01), Donovan
patent: 6921538 (2005-07-01), Donovan
patent: 7063860 (2006-06-01), Chancellor et al.
patent: 7270287 (2007-09-01), First
patent: 7357934 (2008-04-01), Donovan et al.
patent: 2001/0036943 (2001-11-01), Coe et al.
patent: 2001/0053369 (2001-12-01), Donovan
patent: 2002/0192239 (2002-12-01), Borodic et al.
patent: 2003/0133951 (2003-07-01), Coe et al.
patent: 2003/0202990 (2003-10-01), Donovan
patent: 2004/0018212 (2004-01-01), Aoki
patent: 2004/0018213 (2004-01-01), Aoki
patent: 2004/0062776 (2004-04-01), Voet
patent: 2004/0146532 (2004-07-01), Gil et al.
patent: 2004/0213814 (2004-10-01), Ackerman
patent: 2005/0147626 (2005-07-01), Blumenfeld
patent: 2006/0083758 (2006-04-01), Dadas
patent: 2008/0003318 (2008-01-01), Aoki et al.
patent: 10 150 415 (2003-05-01), None
patent: 0 760 681 (1999-01-01), None
patent: 2228263 (1990-08-01), None
patent: WO 99/55359 (1999-11-01), None
Westra, I et al, Can. J. Ophthalmol, vol. 26(3), 1991, pp. 148-151, Occult pontine glioma in a patient with hemifacial spasm.
O'Brien, Christopher F, MD, Injection Techniques for Botulinum Toxin using Electromyography and Electrical Stimulation, Muscle and Nerve, Supplement 6, 1997, pp. S176-S180.
Micheli et al, reference of record.
Auchus et al, (1995) reference of record.
Murakami et al, 2001, British Journal of Pharmacology, vol. 134, pp. 507-520, Determination of effects of antiepileptic drugs on SNAREs-mediated hippocampal monoamine release using in vivo microdialysis.
Hainline, B, Psychiatr. Clin. North Am., Sep. 2005, vol. 28(3), pp. 713-735, Chronic pain: pysiological, diagostic, and management considerations. abstract only.
Weintraub, Daniel et al, The Journal of Mangaed Care, vol. 14(2), pp. S59-S69, Parkinson's Diesease- Part 3: Neuropsychiatric symptoms.
Bunevicius, R et al, Mood and anxiety disorders in women with treated hyperthyroidism and opthalmopathy caused by Grave's disease, General Hospital Psychiatry, vol. 27, 2005, pp. 133-139.
de Araujo Filho, G. M. et al, Epilepsy & Behavior, vol. 8, 2006, pp. 606-609 Neuropsychiatric profiles of patients with juvenile myoclonic epilepsy treated with valproate and topiramate.
Auchus, AP et al.,Agitated behaviour relieved following treatment by vasodilators,Neurology, Feb. 1995, vol. 45, No. 2, p. 393.
Baltazar, G., et al., European Journal of Cell Biology, Dec. 2000, vol. 79, No. 12, pp. 883-891.
Bassitt, D. Pastore, et al., Pharmacopsychiatry, Jul. 2000, vol. 33, No. 4, p. 155.
Bejjani, B., et al.,Bilateral subthalamic stimulation for Parkinson's disease by using three-dimensional sterotactic magnetic resonance imaging and electrophysiological guidance,J Neurosurg, Apr. 2000, 92, pp. 615-625.
Bellezza, D. ,et al.,Stereostatic Interstitial Brachytherapy,Text book of stereotactic and functional neurosurgery, McGraw-Hill, 1002, Chpt. 66, pp. 577-580.
Bigalke, H., et al.,Botulinum A neurotoxin inhibits non-cholinergic synaptic transmission in mouse spinal cord neurons in culture,Brain Research, 360 (1985) 318-324.
Bigalke, H., et al.,Tetanus Toxin and botulinum a toxin inhibit release and uptake of various transmitters, as studied with particulate preparations from rat brain and spinal cord,Naunyn-Schmiedeberg's Arch Pharmacol (1981) 316:244-251.
Bolay, H., et al.,Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model,Nature Medicine, vol. 8, No. 2, Feb. 2002, pp. 136-142.
Brem, H., et al.,Placebo-controlled trial of saety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas,The Lancet, vol. 345, Aprl 22, 1995, pp. 1008-1012.
Brem, H., et al.,The safety of interstitial chemotherapy with BCNU-loaded polymer follwed by radiation therapy in the treatment of newly diagnosed malignant gliomas: phase I trial,J. of Neuro-Oncology 26:111-123, 1995.
Burn, David J., et al.,Use of Functional Imaging in Parkinsonism and Dementia,Movement Disorders , 2003, vol. 18, Suppl 6, pp. S88-S95.
Burr Leiva, Daniel,The neurochemistry of mania: a hypothesis of etiology and a rationale for treatment,Prog. Neuro-Psychopharmacol & Biol. Psychiat. 1990, vol. 14, pp. 423-429.
Cereda, E., et al,.Medicinal chemistry of muscarinic agonists for the treatment of dementia disorders,Eur J Drug Metab Pharmacokinet, 1994 (3), pp. 179-183.
Clarke, P., et al.,Innervation of substantia nigra neurons by cholinergic afferents from pedunculopontine nucleus in the rat: neuroanatomical and electrophysiological evidence,Neuroscience vol. 23, No. 3, pp. 1011-1019, 1987.
Coffield, et al., Eds: Jankovic, J., et al.,Therapy with Botulinum Toxin,Marcel Dekker, Inc. 1994, p. 5.
Cosgrove, G. Rees, et al.,Cingulotomy in Psychosurgery,Stereotactic and Functional Neurosurgery, 1998, P.L. Gildenberg, Eds., McGraw-Hill Pubs., Chpt. 203, pp. 1965-1979.
Cummings, J. L., et al.,Alzheimer's disease: cognitive and behavioral pharmacotherapy,Connecticut Medicine, Sep. 1997, vol. 61, No. 9, pp. 543-552.
Duggan, Michael J., et al,.A survey of botulinum neurotoxin substrate expression in cells,Movement Disorders, 1005, May, 10(3), p. 376.
Egan, M.F., et al., Schizophrenia Bulletin, 1997, vol. 23, No. 4, pp. 583-609.
Fujimori, S., et al.,Neuropsychiatric disorders and GABA,Nihon shinkei seishin yakurigaku zasshi, Japanese Journaql of Psychopharmacology, Oct. 2004, vol. 45, No. 5, pp. 265-271 (Abstract only).
Fung, L.K., et al.,Pharmacokinetics of Interstitial Delivery of Carmustine, 4-hydroperoxycyclophosphamide, and paclitaxel from a biodegradable polymer implant in the monkey brain,Cancer Research, 58, 672-684, Feb. 15, 1998.
Garcia-Rill, E., et al.,Mesopontine neurons in schizophrenia,Neuroscience vol. 66, No. 2, pp. 321-335, 1995.
Gaspar, L.E., et al.,Permanent Iodine implants for recurrent malignant gliomas,Int. J. Radiation Onocology Biol. Phys., vol. 43, No. 5, pp. 977-982, 1999.
German, D.C., et al.,Mesopontine cholinergic and non-cholinergic neurons in schizophrenia,Neuroscience, vol. 94, No. 1, pp. 33-38, 1999.
Gonelle-Gispert, C., et al.,SNAP-25a and—25b isofoms are both expressed in insulin-secreting cells and can function in insulin secretion,Biochem. J. (1999) 339; pp. 159-165.
Habermann, E., et al.,Tetanus toxin and botulinum A and C neurotoxins inhibit noradrenaline release from cultured mouse brain,J. Neurochemistry, 1988, pp. 522-527.
Habermann, E.,I-Labled Neurotoxin from Clostridium bot

Affiliated with

Also associated with

Rating

Botulinum toxin therapy for neuropsychiatric disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Botulinum toxin therapy for neuropsychiatric disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Botulinum toxin therapy for neuropsychiatric disorders will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4202092